-
News
NewMediaWire | QC Kinetix (Madison
[ad_1] MADISON, WI – (NewMediaWire) – November 7, 2022 – via QC Kinetix — QC Kinetix (Madison – SW) is…
Read More » -
Maximizing heart failure meds within 2 weeks reduced risk of hospital readmission, death
[ad_1] Research Highlights: A multinational, randomized trial evaluated outcomes for people hospitalized with acute heart failure who received a high-intensity…
Read More » -
News
Jupiter Wellness Announces Plan to Spin Off Caring Brands, Inc. as Digital Securities Dividend to Shareholders
Jupiter Wellness, Inc. (Nasdaq:JUPW), today announced that it has plans to transfer and spin-off forty percent (40%) of the Company's…
Read More » -
News
SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimer’s Disease Patients with Agitation
SciSparc Ltd. (Nasdaq: SPRC), today announced positive interim results from its Phase IIa trial of SCI-110 in patients with Alzheimer’s…
Read More » -
Personalized evaluation for chest pain effective, may eliminate unnecessary testing
[ad_1] Research Highlights: For people with stable chest pain, a personalized “precision” testing approach led to more efficient evaluations for…
Read More » -
6 common “heart-health” supplements ineffective at lowering cholesterol compared to statins
[ad_1] Research Highlights: Six widely used dietary supplements promoted for improving heart health – including brands of fish oil, cinnamon,…
Read More » -
Study reinforces need for greater coordination in heart attack care
[ad_1] American Heart Association Scientific Sessions 2022, Abstract 286 Embargoed until 9:42 a.m. CT/ 10:42 a.m. ET Sunday, Nov. 6,…
Read More » -
No difference in heart outcomes found in use of two diuretics to treat blood pressure
[ad_1] Research Highlights: In a study comparing the effectiveness of two high blood pressure medications (both diuretics) among elderly veterans,…
Read More » -
Novel gene-editing therapy shows promise for patients with transthyretin amyloid cardiomyopathy
[ad_1] Research Highlights: In a clinical trial, a single intravenous infusion of NTLA-2001, a novel gene-editing therapy based on CRISPR/Cas9,…
Read More »

